Roche Holding AG’s lung cancer A drug has been found to be superior to a standard treatment in a recent study. Now, the Swiss pharmaceutical company is turning its attention elsewhere. to artificial intelligence to find patients Who can benefit?
When given after surgery to You can remove your own hair by clicking here. lung tumors, Roche’s Alecensa Cut the risk of either cancer According to the FDA, standard chemotherapy reduces recurrences or deaths by 76%. to results From a primary examination of the trial The drug was released on Wednesday. The drug was released on Wednesday. “potentially alter the course of this disease,” Levi Garraway, Chief Medical Officer at Roche, said this in a press release.
Finding patients to treat may be difficult: The study examined the effects on people with an error in a gene called ALK that’s found in only about 4% to 5% lung cancer patients. They are mostly younger and have a lower likelihood of being convicted. to Smoked than usual lung The tumorous growth is a recurring problem. patientsYou can go to the restroom a lot. undiagnosed Early on.
Roche will solve the problem by using an AI Medial EarlySign Ltd., an Israeli tech company, has partnered with us to create a new technology. to Helping doctors to determine when to CT scans are a good option. While the technology, called LungFlag, doesn’t currently detect ALK-positive patients, the company said on Saturday that it’s actively exploring how to Expand it to benefit them.
It will help find Charlie Fuchs said that it is possible to remove tumors while they are still small and before they have spread, as well as if necessary, during the time of surgery. Roche’s Head of Oncology and Hematology Drug Development
“Sometimes when you really use deep data algorithms, you may find things that identify people who are non-smokers and yet at risk,” Fuchs told an interviewer. “We hope more patients can be found early and benefit from this.”
Roche has stated that it will file the lawsuit Alecensa The results of the study will be submitted to regulators for their approval. The results were announced at the European Society for Medical Oncology conference in Madrid. Alecensa Already approved in the US and Europe, Japan, China, patients ALK-positive metastatic carcinoma lung cancer.
Analysts predict that Alecensa This year, the drug will bring in 1.56 billion Swiss Francs ($1.75billion) in sales. It would be a blockbuster drug even though it only treats a small percentage of the population. lung cancer patients shows that effective drugs don’t have to Serving a large population of patients to Fuchs says that the scientific and economic successes will be a success.